T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease

Mohammad Haris, Santosh K. Yadav, Arshi Rizwan, Anup Singh, Kejia Cai, Deepak Kaura, Ena Wang, Christos Davatzikos, John Q. Trojanowski, Elias R. Melhem, Francesco M. Marincola, Arijitt Borthakur

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T) imaging and CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer's disease (AD) patients from mild cognitive impairment (MCI) and control subjects. With informed consent, AD (n = 27), MCI (n = 17) and control (n = 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40 ms). T maps were generated by pixel-wise fitting of signal intensity as a function of the spin-lock pulse duration. T values from gray matter (GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T and CSF biomarkers as variables was performed to classify each group. T was able to predict 77.3% controls and 40.0% MCI while CSF biomarkers predicted 81.8% controls and 46.7% MCI. T and CSF biomarkers in combination predicted 86.4% controls and 66.7% MCI. When comparing controls with AD, T predicted 68.2% controls and 73.9% AD, while CSF biomarkers predicted 77.3% controls and 78.3% for AD. Combination of T and CSF biomarkers improved the prediction rate to 81.8% for controls and 82.6% for AD. Similarly, on comparing MCI with AD, T predicted 35.3% MCI and 81.9% AD, whereas CSF biomarkers predicted 53.3% MCI and 83.0% AD. Collectively CSF biomarkers and T were able to predict 59.3% MCI and 84.6% AD. On receiver operating characteristic analysis T showed higher sensitivity while CSF biomarkers showed greater specificity in delineating MCI and AD from controls. No significant correlation between T and CSF biomarkers, between T and age, and between CSF biomarkers and age was observed. The combined use of T and CSF biomarkers have promise to improve the early and specific diagnosis of AD. Furthermore, disease progression form MCI to AD might be easily tracked using these two parameters in combination.

Original languageEnglish
Pages (from-to)598-604
Number of pages7
JournalNeuroImage: Clinical
Volume7
DOIs
Publication statusPublished - 2015

Fingerprint

Alzheimer Disease
Biomarkers
Cognitive Dysfunction
Temporal Lobe
Informed Consent
ROC Curve
Disease Progression
Early Diagnosis
Logistic Models
Magnetic Resonance Imaging
Brain

Keywords

  • Alzheimer's disease
  • CSF biomarkers
  • Medial temporal lobe
  • Mild cognitive impairment
  • T1rho

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. / Haris, Mohammad; Yadav, Santosh K.; Rizwan, Arshi; Singh, Anup; Cai, Kejia; Kaura, Deepak; Wang, Ena; Davatzikos, Christos; Trojanowski, John Q.; Melhem, Elias R.; Marincola, Francesco M.; Borthakur, Arijitt.

In: NeuroImage: Clinical, Vol. 7, 2015, p. 598-604.

Research output: Contribution to journalArticle

Haris, M, Yadav, SK, Rizwan, A, Singh, A, Cai, K, Kaura, D, Wang, E, Davatzikos, C, Trojanowski, JQ, Melhem, ER, Marincola, FM & Borthakur, A 2015, 'T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease', NeuroImage: Clinical, vol. 7, pp. 598-604. https://doi.org/10.1016/j.nicl.2015.02.016
Haris, Mohammad ; Yadav, Santosh K. ; Rizwan, Arshi ; Singh, Anup ; Cai, Kejia ; Kaura, Deepak ; Wang, Ena ; Davatzikos, Christos ; Trojanowski, John Q. ; Melhem, Elias R. ; Marincola, Francesco M. ; Borthakur, Arijitt. / T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. In: NeuroImage: Clinical. 2015 ; Vol. 7. pp. 598-604.
@article{fa7c7ce6e243437f84e059aef7e3fd01,
title = "T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease",
abstract = "In the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T1ρ) imaging and CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer's disease (AD) patients from mild cognitive impairment (MCI) and control subjects. With informed consent, AD (n = 27), MCI (n = 17) and control (n = 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T1ρ images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40 ms). T1ρ maps were generated by pixel-wise fitting of signal intensity as a function of the spin-lock pulse duration. T1ρ values from gray matter (GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T1ρ and CSF biomarkers as variables was performed to classify each group. T1ρ was able to predict 77.3{\%} controls and 40.0{\%} MCI while CSF biomarkers predicted 81.8{\%} controls and 46.7{\%} MCI. T1ρ and CSF biomarkers in combination predicted 86.4{\%} controls and 66.7{\%} MCI. When comparing controls with AD, T1ρ predicted 68.2{\%} controls and 73.9{\%} AD, while CSF biomarkers predicted 77.3{\%} controls and 78.3{\%} for AD. Combination of T1ρ and CSF biomarkers improved the prediction rate to 81.8{\%} for controls and 82.6{\%} for AD. Similarly, on comparing MCI with AD, T1ρ predicted 35.3{\%} MCI and 81.9{\%} AD, whereas CSF biomarkers predicted 53.3{\%} MCI and 83.0{\%} AD. Collectively CSF biomarkers and T1ρ were able to predict 59.3{\%} MCI and 84.6{\%} AD. On receiver operating characteristic analysis T1ρ showed higher sensitivity while CSF biomarkers showed greater specificity in delineating MCI and AD from controls. No significant correlation between T1ρ and CSF biomarkers, between T1ρ and age, and between CSF biomarkers and age was observed. The combined use of T1ρ and CSF biomarkers have promise to improve the early and specific diagnosis of AD. Furthermore, disease progression form MCI to AD might be easily tracked using these two parameters in combination.",
keywords = "Alzheimer's disease, CSF biomarkers, Medial temporal lobe, Mild cognitive impairment, T1rho",
author = "Mohammad Haris and Yadav, {Santosh K.} and Arshi Rizwan and Anup Singh and Kejia Cai and Deepak Kaura and Ena Wang and Christos Davatzikos and Trojanowski, {John Q.} and Melhem, {Elias R.} and Marincola, {Francesco M.} and Arijitt Borthakur",
year = "2015",
doi = "10.1016/j.nicl.2015.02.016",
language = "English",
volume = "7",
pages = "598--604",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease

AU - Haris, Mohammad

AU - Yadav, Santosh K.

AU - Rizwan, Arshi

AU - Singh, Anup

AU - Cai, Kejia

AU - Kaura, Deepak

AU - Wang, Ena

AU - Davatzikos, Christos

AU - Trojanowski, John Q.

AU - Melhem, Elias R.

AU - Marincola, Francesco M.

AU - Borthakur, Arijitt

PY - 2015

Y1 - 2015

N2 - In the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T1ρ) imaging and CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer's disease (AD) patients from mild cognitive impairment (MCI) and control subjects. With informed consent, AD (n = 27), MCI (n = 17) and control (n = 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T1ρ images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40 ms). T1ρ maps were generated by pixel-wise fitting of signal intensity as a function of the spin-lock pulse duration. T1ρ values from gray matter (GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T1ρ and CSF biomarkers as variables was performed to classify each group. T1ρ was able to predict 77.3% controls and 40.0% MCI while CSF biomarkers predicted 81.8% controls and 46.7% MCI. T1ρ and CSF biomarkers in combination predicted 86.4% controls and 66.7% MCI. When comparing controls with AD, T1ρ predicted 68.2% controls and 73.9% AD, while CSF biomarkers predicted 77.3% controls and 78.3% for AD. Combination of T1ρ and CSF biomarkers improved the prediction rate to 81.8% for controls and 82.6% for AD. Similarly, on comparing MCI with AD, T1ρ predicted 35.3% MCI and 81.9% AD, whereas CSF biomarkers predicted 53.3% MCI and 83.0% AD. Collectively CSF biomarkers and T1ρ were able to predict 59.3% MCI and 84.6% AD. On receiver operating characteristic analysis T1ρ showed higher sensitivity while CSF biomarkers showed greater specificity in delineating MCI and AD from controls. No significant correlation between T1ρ and CSF biomarkers, between T1ρ and age, and between CSF biomarkers and age was observed. The combined use of T1ρ and CSF biomarkers have promise to improve the early and specific diagnosis of AD. Furthermore, disease progression form MCI to AD might be easily tracked using these two parameters in combination.

AB - In the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T1ρ) imaging and CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer's disease (AD) patients from mild cognitive impairment (MCI) and control subjects. With informed consent, AD (n = 27), MCI (n = 17) and control (n = 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T1ρ images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40 ms). T1ρ maps were generated by pixel-wise fitting of signal intensity as a function of the spin-lock pulse duration. T1ρ values from gray matter (GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T1ρ and CSF biomarkers as variables was performed to classify each group. T1ρ was able to predict 77.3% controls and 40.0% MCI while CSF biomarkers predicted 81.8% controls and 46.7% MCI. T1ρ and CSF biomarkers in combination predicted 86.4% controls and 66.7% MCI. When comparing controls with AD, T1ρ predicted 68.2% controls and 73.9% AD, while CSF biomarkers predicted 77.3% controls and 78.3% for AD. Combination of T1ρ and CSF biomarkers improved the prediction rate to 81.8% for controls and 82.6% for AD. Similarly, on comparing MCI with AD, T1ρ predicted 35.3% MCI and 81.9% AD, whereas CSF biomarkers predicted 53.3% MCI and 83.0% AD. Collectively CSF biomarkers and T1ρ were able to predict 59.3% MCI and 84.6% AD. On receiver operating characteristic analysis T1ρ showed higher sensitivity while CSF biomarkers showed greater specificity in delineating MCI and AD from controls. No significant correlation between T1ρ and CSF biomarkers, between T1ρ and age, and between CSF biomarkers and age was observed. The combined use of T1ρ and CSF biomarkers have promise to improve the early and specific diagnosis of AD. Furthermore, disease progression form MCI to AD might be easily tracked using these two parameters in combination.

KW - Alzheimer's disease

KW - CSF biomarkers

KW - Medial temporal lobe

KW - Mild cognitive impairment

KW - T1rho

UR - http://www.scopus.com/inward/record.url?scp=84924184565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924184565&partnerID=8YFLogxK

U2 - 10.1016/j.nicl.2015.02.016

DO - 10.1016/j.nicl.2015.02.016

M3 - Article

C2 - 25844314

AN - SCOPUS:84924184565

VL - 7

SP - 598

EP - 604

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

ER -